Silence Therapeutics (SLN) Net Margin (2024 - 2026)

Silence Therapeutics has disclosed Net Margin across 3 years of filings, most recently posting 3544.31% for Q1 2026.

• Net Margin for Q1 2026 came in at 3544.31%, up 1654724.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9339.51% (down 908130.0% YoY), and the FY2025 annual result was 16044.72%, down 1593998.0% from the prior year.
• Net Margin came in at 3544.31% for Q1 2026 at Silence Therapeutics, up from 37788.24% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 48.61% in Q4 2024 to a low of 37788.24% in Q4 2025.
• The 3-year median for Net Margin is 3544.31% (2026), against an average of 10359.36%.
• Across the five-year window, Net Margin sank 3783685 bps in 2025 and jumped 1654724 bps in 2026, its largest moves.
• Silence Therapeutics' Net Margin stood at 48.61% in 2024, then plunged by 77830 bps to 37788.24% in 2025, then soared by 91 bps to 3544.31% in 2026.
• The last three Net Margin figures came in at 3544.31% (Q1 2026), 37788.24% (Q4 2025), and 13181.13% (Q3 2025), per Business Quant data.